News

Filter

AstraZeneca and Amgen's  brodalumab achieves primary endpoint in Phase III trial for plaque psoriasis

AstraZeneca and Amgen's brodalumab achieves primary endpoint in Phase III trial for plaque psoriasis

12-11-2014

Anglo-Swedish drug major AstraZeneca and USA-based Amgen, the world’s largest independent biotech firm,…

AmgenAstraZenecaBiotechnologybrodalumabDermatologicalsResearchStelara

Onglyza meets primary safety endpoint in SAVOR CV outcomes trial

02-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb (NYSE: MBY) today…

AstraZenecaBristol-Myers SquibbCardio-vascularDermatologicalsOnglyzaPharmaceuticalResearch

AstraZeneca gains rights to Heptares GPCR drug for $6.25 million upfront

31-05-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that it has entered a four-year…

AstraZenecaDermatologicalsHeptares TherapeuticsLicensingNeurologicalPharmaceuticalResearch

AstraZeneca and Galderma link up for new dermatological treatments

08-03-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Switzerland’s Galderma Pharma have entered into…

AstraZenecaDermatologicalsGaldermaLicensingPharmaceuticalResearch

COMPANY SPOTLIGHT

Menarini

Back to top